Among people with type 2 diabetes and obesity who undergo metabolic surgery, Roux-en-Y gastric bypass is associated with a lower risk for major adverse cardiovascular events than sleeve gastrectomy, suggests a secondary analysis of a cohort study.
Metabolic surgery can result in type 2 diabetes remission lasting for at least 10 years, and people who relapse still achieve markedly improved glycemic control, shows follow-up from a randomized trial published in The Lancet.
Bariatric surgery is associated with a reduced prevalence of pancreatic cancer in obese individuals with type 2 diabetes, suggest findings from a population-based study presented at UEG Week Virtual 2020.
Weight loss after gastric bypass surgery results in important cardiovascular and renal benefits for obese people with type 2 diabetes, irrespective of their baseline renal function, observational cohort study data show.
People with obesity and type 2 diabetes who undergo gastric bypass surgery have higher rates of diabetes remission after 1 year than those undergoing sleeve gastrectomy, indicate findings from the Oseberg trial.